UKE managing international "GUIDE.MRD" research into cancer

Scientists are researching the use of liquid biopsies for diagnosing minimal residual disease (MRD) as part of the "GUIDing multi-modal thErapies against Minimal Residual Disease by liquid biopsies" project. Radiology methods used to detect these residual tumour cells, which require chemotherapy or radiotherapy in the case of MRD, have failed so far.  However, circulating tumour DNA (ctDNA) can be detected in the blood, prompting researchers to develop a tool for early detection and targeted multimodal treatment of metastases.

"I congratulate all those institutions involved in this great success, which will strengthen Hamburg as a centre of health and cancer research," said Katharina Fegebank, Senator for Science and Research. "The early detection of metastases is one of the most important goals in cancer research, as metastases are the main causes of aggressive cancer. Earlier diagnosis using a blood test should open up the possibility of timely therapeutic intervention through liquid biopsy," said Prof. Pantel, Director of the Institute of Tumor Biology at UKE. "The standardised use of liquid biopsies in oncological MRD diagnostics can lead to precise cancer therapies modified to the individual clinical picture and giving patients the best possible therapy. The significant EU funding for this important research project reflects UKE's outstanding expertise in oncological research," said Prof. Dr. Blanche Schwappach-Pignataro, UKE Board Member and Dean of the Medical Faculty.

nj/mm/sb/pb